Assessment of Paclitaxel-Induced Neuropathy

Active, not recruiting

• Conditions: Breast Cancer; Cancer; Ovarian Cancer

• Registration Number: NCT01953159
• Lead Sponsor: University of Chicago

Brief Summary

The purpose of this study is to collect clinical data, blood samples, and self reported symptoms from patients that experience unusually severe neuropathy after treatment with paclitaxel. This data will be used to develop predictive markers for neuropathy. Blood samples will be used to create induced pluripotent stem (iPS) cells and eventually artificial nerve cells to be used to study neuropathy in the lab.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-08-29
• Study First Submitted: 2013-09-25
• Study First Submitted QC: 2013-09-27
• Study First Posted: 2013-09-30
• Status Verified: 2025-06
• Last Update Submitted: 2025-06-06
• Last Update Posted: 2025-06-08
• Primary Completion: 2027-05-19
• Study Completion: 2027-12

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: Female
• Target Recruitment: 43

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Validation of polygenic risk score	2 years	Patients will be assessed for neuropathy symptoms and blood samples will be analyzed to detect potential predictive markers

Trial Locations

Locations (1)

University of Chicago Comprehensive Cancer Center; 🇺🇸 Chicago, Illinois, United States